Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc.

Similar securities

Based on sector and market capitalization

Report issue